ANSWER: B

Rationale:

The proximal convoluted tubule (PCT) is responsible for reabsorbing approximately 65% of the filtered sodium load, making it the dominant site of sodium reabsorption in the nephron. The primary luminal mechanism is NHE3, which exchanges one intracellular proton for one luminal sodium ion; the proton is regenerated through carbonic anhydrase-catalyzed conversion of carbonic acid to water and carbon dioxide, sustaining the driving gradient. This PCT segment is the target of carbonic anhydrase inhibitors such as acetazolamide but is not the primary site of action of loop diuretics or thiazides.

• Option A: Option A is incorrect: the TAL does reabsorb approximately 25% of filtered sodium via NKCC2 — these are accurate figures for that segment — but the TAL is not the largest contributor to overall sodium reabsorption; the PCT with 65% occupies that role.
• Option C: Option C is incorrect: the DCT and NCC are accurately paired, but the DCT handles only 5–8% of filtered sodium, not the largest fraction.
• Option D: Option D is incorrect: the collecting duct accounts for only 2–3% of sodium reabsorption via ENaC; the figure of 25–30% is a significant overstatement and the CD is the smallest contributor among the major segments.
• Option E: Option E is incorrect: SGLT2 is expressed in the early PCT and reabsorbs glucose cotransported with sodium, but it does not account for 40% of filtered sodium; NHE3 is the dominant luminal sodium transporter in the PCT, and SGLT2 inhibitors (gliflozins) are a distinct drug class acting on glucose cotransport.

ANSWER: D

Rationale:

In the thick ascending limb (TAL), NKCC2 cotransports one sodium, one potassium, and two chloride ions into the cell per cycle. The potassium that enters the cell is recycled back into the lumen via apical ROMK channels, creating a net positive charge in the tubular lumen relative to the interstitium — the lumen-positive transepithelial potential. This lumen-positive electrical gradient is the primary driving force for paracellular reabsorption of divalent cations, including calcium and magnesium, through claudin-16 and claudin-19 channels in the tight junctions. When loop diuretics block NKCC2, the lumen-positive potential is abolished, paracellular calcium and magnesium reabsorption ceases, and both ions are lost in the urine. This calciuretic effect makes loop diuretics useful in acute hypercalcemia; the concurrent magnesiuresis contributes to hypomagnesemia that can render hypokalemia refractory to potassium supplementation alone.

• Option A: Option A is incorrect: loop diuretics do not suppress PTH secretion; calciuresis is a direct tubular effect in the TAL independent of PTH-mediated mechanisms in the DCT.
• Option B: Option B is incorrect: loop diuretics do not block NCX1; NCX1 on the basolateral membrane exports calcium into the interstitium and is not the target of loop diuretics; the calciuretic mechanism is loss of the paracellular lumen-positive gradient, not basolateral exchanger blockade.
• Option C: Option C is incorrect: loop diuretics do not inhibit carbonic anhydrase; carbonic anhydrase inhibition in the PCT is the mechanism of acetazolamide, a distinct drug class; loop diuretic calciuresis is a TAL phenomenon.
• Option E: Option E is incorrect: no such volume-sensitive chloride channel competing with paracellular calcium flux is the mechanism of loop diuretic calciuresis; this option describes a physiologically fictitious pathway.

ANSWER: A

Rationale:

Furosemide is the most widely prescribed loop diuretic but is pharmacokinetically unreliable: oral bioavailability ranges from 10% to 90% across individuals, the half-life is approximately 1.5–2 hours, and approximately 65% is renally cleared via tubular secretion. In hospitalized patients with bowel wall edema from decompensated heart failure, intestinal absorption is further impaired, making oral furosemide particularly unpredictable in the acute setting. Torsemide has oral bioavailability of 80–90%, a longer half-life of 3–4 hours, and approximately 80% hepatic metabolism, so its pharmacokinetics are less affected by renal impairment. Despite these pharmacokinetic advantages, the TRANSFORM-HF trial — a pragmatic randomized trial comparing torsemide with furosemide after hospitalization for heart failure — found no significant difference in all-cause mortality at one year; secondary outcomes showed marginal trends favoring torsemide but no definitive superiority.

• Option B: Option B is incorrect: furosemide does not have superior bioavailability; its variable and often low oral bioavailability is its principal pharmacokinetic weakness compared with torsemide; TRANSFORM-HF did not show increased readmission with torsemide.
• Option C: Option C is incorrect: torsemide and furosemide do not share equivalent bioavailability; torsemide's pharmacokinetic advantage is predominantly hepatic metabolism, not exclusive renal elimination — furosemide is predominantly renally eliminated.
• Option D: Option D is incorrect: both loop diuretics are highly protein-bound and reach the tubular lumen by active OAT-mediated secretion, not glomerular filtration; lower protein binding is not the mechanism of torsemide's advantage.
• Option E: Option E is incorrect: TRANSFORM-HF did not demonstrate a significant all-cause mortality benefit for torsemide over furosemide; no guideline currently designates torsemide as the preferred loop diuretic on the basis of mortality data.

ANSWER: C

Rationale:

Loop diuretics are highly protein-bound — furosemide approximately 98% — and are therefore minimally filtered at the glomerulus. They reach their luminal site of action on NKCC2 by active secretion via OAT1 and OAT3 transporters located on the basolateral (blood-facing) membrane of the proximal convoluted tubule (PCT). In CKD, plasma accumulates endogenous uremic organic anions such as indoxyl sulfate, p-cresyl sulfate, and hippuric acid, as well as exogenous organic anions from concurrent medications. These anions compete with loop diuretics for OAT binding sites, reducing the rate of tubular secretion and thereby lowering the luminal drug concentration achievable at any given systemic dose. Because of the sigmoidal dose-response relationship of loop diuretics, a luminal concentration below threshold produces zero natriuresis regardless of the systemic dose administered. The correct clinical response is dose escalation to restore adequate luminal concentration and overcome OAT competition.

• Option A: Option A is incorrect: loop diuretics are not freely filtered; their high protein binding (approximately 98% for furosemide) means that less than 2% is presented to the glomerular filtrate, making filtration a negligible delivery route; OAT-mediated secretion is the rate-limiting step.
• Option B: Option B is incorrect: loop diuretics do not cross the TAL luminal membrane by passive diffusion; they act on the luminal face of NKCC2 after being secreted into the proximal tubular lumen and carried distally by tubular flow.
• Option D: Option D is incorrect: P-glycoprotein (ABCB1) is a luminal efflux transporter that exports drugs from cells into the lumen in some segments, but it is not the primary transporter governing loop diuretic delivery; OAT1/OAT3 on the basolateral PCT membrane are the established rate-limiting transporters.
• Option E: Option E is incorrect: countercurrent exchange of drug molecules from peritubular capillaries into the tubular lumen is not a recognized mechanism of loop diuretic delivery; no such pharmacokinetic recycling pathway has been established for this drug class.

ANSWER: E

Rationale:

Furosemide, bumetanide, and torsemide are all sulfonamide-based compounds. Ethacrynic acid is chemically distinct — it is a phenoxyacetic acid derivative with no sulfonamide group — making it the only loop diuretic available as an alternative for patients with documented sulfonamide hypersensitivity. The clinical trade-off is significant: ethacrynic acid carries the highest ototoxic risk of any agent in the loop diuretic class. All loop diuretics can cause ototoxicity through inhibition of NKCC1 in the stria vascularis of the cochlea, disrupting endolymph ion homeostasis, but this risk is most pronounced with ethacrynic acid. As a result, it is reserved for specific clinical situations and is rarely prescribed.

• Option A: Option A is incorrect: furosemide does have clinically significant ototoxic potential, particularly at high doses or with concurrent aminoglycoside use; its sulfonamide structure does not confer cochlear protection.
• Option B: Option B is incorrect: furosemide is predominantly renally eliminated via tubular secretion; torsemide is the loop diuretic with predominantly hepatic metabolism; this is the reverse of what option B states.
• Option C: Option C is incorrect: bumetanide is approximately 40 times as potent as furosemide on a milligram basis, not 1:1; the standard conversion is approximately 1 mg bumetanide = 40 mg furosemide; they are not interchangeable at equal doses.
• Option D: Option D is incorrect: ethacrynic acid does inhibit NKCC1 in the stria vascularis and carries the highest, not lowest, ototoxic risk of the loop diuretic class; it is contraindicated, not preferred, in patients at high risk for hearing loss.

ANSWER: B

Rationale:

The sigmoidal (S-shaped) concentration-response relationship is the defining pharmacodynamic characteristic of loop diuretics at the tubular level. Below a threshold luminal drug concentration, NKCC2 inhibition is insufficient to produce measurable natriuresis. Once the threshold is exceeded, the natriuretic response rises steeply with small further increases in luminal concentration. Above a ceiling concentration, NKCC2 is maximally occupied and additional drug produces no additional effect — the natriuretic response plateaus regardless of dose escalation. In CKD, uremic organic anion competition at OAT transporters elevates the threshold (more systemic drug is required to achieve adequate luminal concentration), and structural nephron loss reduces the maximum achievable natriuresis. Once the ceiling is reached, the appropriate maneuver is sequential nephron blockade: adding a thiazide-like agent such as metolazone to block NCC in the distal convoluted tubule (DCT) simultaneously with NKCC2 blockade in the TAL, preventing the DCT from compensating for the proximal natriuresis.

• Option A: Option A is incorrect: the dose-response is not linear; the sigmoidal shape with threshold and ceiling is a fundamental pharmacodynamic property of loop diuretics, not a consequence of toxicity.
• Option C: Option C is incorrect: while OAT saturation at the basolateral membrane is a theoretical construct, the ceiling effect is defined pharmacodynamically by maximal NKCC2 occupancy at the luminal surface, not by basolateral transporter saturation; doses above the ceiling do reach the lumen but produce no additional NKCC2 blockade.
• Option D: Option D is incorrect: loop diuretics do not exhibit a bell-shaped dose-response; no paradoxical reduction in natriuresis occurs at high doses through NKCC2 upregulation; the curve rises to a plateau and remains there.
• Option E: Option E is incorrect: the dose-response above threshold is steep, not flat; the distinction between threshold, steep portion, and ceiling is clinically essential — doses at the ceiling are wasted, but doses between threshold and ceiling produce meaningfully greater natriuresis.

ANSWER: D

Rationale:

NCC transport in the DCT is electroneutral — one sodium and one chloride are cotransported without net charge movement — so NCC blockade does not generate a lumen-positive potential and paracellular calcium reabsorption is not directly affected by a charge mechanism. Instead, calcium retention occurs through a transcellular pathway: NCC blockade reduces the rate of sodium entry into the DCT cell, lowering intracellular sodium concentration. This lower intracellular sodium reduces competition at the basolateral Na-Ca exchanger isoform 1 (NCX1), which operates by exchanging three sodium ions moving inward for one calcium ion moving outward. With less intracellular sodium competing, NCX1 can export calcium into the interstitium more efficiently, lowering intracellular calcium concentration. The resulting low intracellular calcium then augments the electrochemical gradient driving calcium entry from the tubular lumen through apical TRPV5 channels. The net effect is increased transcellular calcium reabsorption, reducing urinary calcium. This calcium-sparing property makes thiazides first-line pharmacological therapy for recurrent calcium nephrolithiasis.

• Option A: Option A is incorrect: thiazides do not directly activate PTH receptors; PTH acts through G protein-coupled receptors to regulate calcium handling, but the thiazide calcium-sparing effect is a direct consequence of NCC blockade and its intracellular sodium effects, independent of PTH.
• Option B: Option B is incorrect: NCC is an electroneutral cotransporter and its blockade does not generate a lumen-positive potential; the lumen-positive mechanism is specific to the TAL where NKCC2 activity and apical ROMK recycling create positive luminal charge.
• Option C: Option C is incorrect: thiazides do not cause significant afferent arteriolar vasoconstriction or clinically meaningful GFR reduction; the calcium-sparing effect is a direct tubular mechanism in the DCT, not a filtered load phenomenon.
• Option E: Option E is incorrect: thiazides do not block mineralocorticoid receptors; the calcium-sparing mechanism operates in the DCT via NCX1 and TRPV5, not in the collecting duct through aldosterone antagonism.

ANSWER: A

Rationale:

The pharmacokinetic distinction between chlorthalidone and HCTZ is clinically meaningful: chlorthalidone has a half-life of 40–60 hours, whereas HCTZ has a half-life of 6–15 hours. This difference means chlorthalidone provides more sustained antihypertensive effect across the full 24-hour dosing interval, including the early morning surge period when myocardial infarction and stroke events are most frequent. The ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) randomized over 33,000 high-risk hypertensive patients to chlorthalidone, amlodipine, or lisinopril. Chlorthalidone outperformed lisinopril in reducing fatal and nonfatal stroke and was superior to amlodipine in preventing heart failure hospitalization, supporting its position as the guideline-preferred thiazide-class agent.

• Option B: Option B is incorrect: ALLHAT compared chlorthalidone with amlodipine and lisinopril, not with HCTZ; HCTZ does not appear in ALLHAT; the trial supports chlorthalidone, not HCTZ, and chlorthalidone is first-line, not a reserve agent.
• Option C: Option C is incorrect: chlorthalidone and HCTZ do not have equivalent half-lives; the 40–60 hour vs. 6–15 hour difference is a key pharmacokinetic distinction; ALLHAT evaluated cardiovascular outcomes, not nephrolithiasis events.
• Option D: Option D is incorrect: chlorthalidone is a thiazide-like agent that acts on NCC in the DCT; it does not inhibit NKCC2 in the TAL — that is the mechanism of loop diuretics; its activity at low GFR does not match the profile of metolazone, which has a proximal tubular action.
• Option E: Option E is incorrect: ALLHAT did not demonstrate a significant all-cause mortality benefit for chlorthalidone over amlodipine or lisinopril; the primary endpoint (fatal coronary heart disease or nonfatal myocardial infarction) showed no significant difference among the three arms; chlorthalidone's advantages were in stroke and heart failure secondary endpoints.

ANSWER: C

Rationale:

Metolazone is a quinazoline sulfonamide classified as a thiazide-like diuretic whose primary mechanism is NCC blockade in the distal convoluted tubule (DCT), shared with conventional thiazides and HCTZ. What distinguishes metolazone is that it retains clinically meaningful diuretic activity at GFR values below 30 mL/min/1.73 m², where HCTZ and most conventional thiazides lose effectiveness. This property is attributed in part to an additional proximal tubular action that provides supplemental natriuresis beyond what DCT-based NCC inhibition alone can achieve when nephron mass is reduced. In the setting of loop-resistant volume overload, adding metolazone to furosemide creates sequential nephron blockade: furosemide inhibits NKCC2 in the TAL while metolazone inhibits NCC in the DCT. Without this distal block, DCT and collecting duct cells compensatorily hypertrophy and upregulate NCC and ENaC to reclaim sodium lost upstream — blunting the net loop diuretic effect. The combination can produce dramatic natriuresis and requires electrolyte and renal function monitoring within 24–48 hours.

• Option A: Option A is incorrect: metolazone is not a loop diuretic; it is a thiazide-like agent acting on NCC, not NKCC2; classifying it as a loop diuretic would misidentify both its chemical class and its mechanism.
• Option B: Option B is incorrect: the rationale for metolazone's GFR-independent efficacy is not lower protein binding; the proximal tubular action is the established pharmacological explanation, not preferential filtration-based delivery.
• Option D: Option D is incorrect: metolazone does not produce natriuresis through aldosterone-mediated ENaC upregulation; aldosterone upregulates ENaC in a way that increases sodium reabsorption, opposing natriuresis; metolazone's benefit is NCC blockade plus proximal action, not aldosterone activation.
• Option E: Option E is incorrect: metolazone, like other thiazide-class agents, depends on organic anion transporter secretion for luminal delivery; passive lipid diffusion across the intact tubular epithelium is not the established route of delivery for this drug class.

ANSWER: E

Rationale:

The mechanisms of hypokalemia differ between the two classes. Loop diuretics generate hypokalemia through two converging effects: NKCC2 blockade in the TAL directly eliminates potassium reabsorption at that segment, and the massive increase in tubular flow and sodium delivery to the collecting duct (CD) creates a high luminal sodium concentration. ENaC (epithelial sodium channel)-mediated sodium absorption in CD principal cells carries positive charge inward, creating a lumen-negative transepithelial potential that provides the electrochemical driving force for ROMK-mediated potassium secretion into the lumen. Thiazides generate hypokalemia by a different primary pathway: NCC blockade in the DCT produces volume contraction that activates the renin-angiotensin-aldosterone system, generating secondary hyperaldosteronism. Aldosterone upregulates ENaC and ROMK expression in CD principal cells, driving kaliuresis through the same lumen-negative potential mechanism but initiated through hormonal signaling rather than direct high-sodium delivery.

• Option A: Option A is incorrect: neither loop nor thiazide diuretics directly inhibit basolateral Na/K-ATPase; inhibiting the Na/K-ATPase would collapse the sodium gradient that drives all active transport in the nephron and would be acutely toxic to tubular cells.
• Option B: Option B is incorrect: loop diuretics do not cause hypokalemia through PTH-mediated ROMK activation in the TAL; thiazides do not directly block basolateral KCC transporters; both attributions are mechanistically inaccurate.
• Option C: Option C is incorrect: while secondary hyperaldosteronism contributes to both, it is not the exclusive or even primary acute mechanism for loop diuretic-induced hypokalemia; the direct increase in CD sodium delivery is the dominant acute mechanism for loop diuretics, independent of volume-mediated aldosterone changes.
• Option D: Option D is incorrect: loop diuretics do not block aldosterone receptors — that is the mechanism of spironolactone and eplerenone; thiazides do not directly inhibit ROMK channels in the DCT; these descriptions invert the actual mechanisms.

ANSWER: B

Rationale:

Intracellular magnesium (Mg²⁺) acts as a voltage-dependent blocker of ROMK (Kir1.1) channels in the principal cells of the collecting duct (CD). When intracellular magnesium is present at physiological concentrations, it physically occludes the cytoplasmic face of the channel pore, limiting potassium secretion to rates appropriate for potassium homeostasis. When magnesium is depleted — as occurs with loop diuretic-induced magnesiuresis (from loss of the TAL lumen-positive potential that drives paracellular magnesium reabsorption) or thiazide-induced downregulation of TRPM6 in the DCT — ROMK channels lose this magnesium block and remain constitutively open. The result is obligatory, unregulated potassium secretion from principal cells into the tubular lumen. No amount of oral or IV potassium supplementation can overcome this channel-level leak until intracellular magnesium is restored, because the channel remains open regardless of the potassium electrochemical gradient. Concurrent magnesium repletion is therefore mandatory before potassium levels will normalize.

• Option A: Option A is incorrect: magnesium depletion does not reduce aldosterone receptor affinity or activate ligand-independent mineralocorticoid receptor signaling; the refractory hypokalemia mechanism is ROMK channel disinhibition at the principal cell level, not an aldosterone-receptor interaction.
• Option C: Option C is incorrect: hypomagnesemia does not relieve magnesium-dependent autoinhibition of NKCC2; NKCC2 activity is not physiologically regulated by intracellular magnesium in this way; the mechanism of refractory hypokalemia is a distal CD phenomenon, not a TAL feedback loop.
• Option D: Option D is incorrect: carbonic anhydrase activity is not meaningfully regulated by magnesium in a clinically established pathway; the mechanism of refractory hypokalemia is ROMK disinhibition in the CD, not a pH-mediated PCT-to-CD bicarbonate cascade.
• Option E: Option E is incorrect: while both hypokalemia and hypomagnesemia result from diuretic-induced tubular losses, their tubular mechanisms differ — magnesium loss from the TAL (paracellular) versus potassium loss from the CD (ROMK-mediated) — and correcting magnesium specifically restores ROMK inhibition; refractory hypokalemia in this context reflects the ROMK disinhibition mechanism, not dose inadequacy.

ANSWER: D

Rationale:

The differential hyponatremia risk between thiazides and loop diuretics is explained by their contrasting effects on renal water handling. Thiazides act in the DCT and impair urinary dilution — the kidney's ability to generate urine that is more dilute than plasma — because NCC is required for generating a dilute tubular fluid in the cortical diluting segment. However, thiazides do not interfere with the medullary concentration gradient, which depends on NKCC2-mediated sodium and chloride reabsorption in the TAL to maintain interstitial hypertonicity. In a patient with non-osmotic ADH secretion (from pain, nausea, volume depletion, or other stimuli), the thiazide-treated kidney cannot dilute the urine but can still produce maximally concentrated urine in response to ADH — the worst possible combination for hyponatremia, because water is retained without the offsetting ability to excrete free water. Loop diuretics, by contrast, block NKCC2 and disrupt the medullary gradient, impairing urinary concentration as well as dilution and producing a near-isotonic urine regardless of ADH levels. This isotonic urine, while voluminous, cannot drive the disproportionate water retention that leads to severe hyponatremia. The classic high-risk patient is an elderly woman on thiazide therapy who develops an acute illness with nausea and pain — both stimuli for non-osmotic ADH release.

• Option A: Option A is incorrect: the differential hyponatremia risk is not primarily driven by differences in ADH secretion between the two classes; it reflects their different effects on urinary diluting versus concentrating capacity.
• Option B: Option B is incorrect: protein binding differences between thiazides and loop diuretics do not explain the differential hyponatremia risk; the mechanism is pharmacodynamic, related to which tubular segment is targeted and what that implies for urinary osmolality.
• Option C: Option C is incorrect: loop diuretics are not more likely to cause hyponatremia than thiazides; this is a well-established clinical observation supported by epidemiological data and explained by the pharmacodynamic mechanism described above.
• Option E: Option E is incorrect: thiazides do not directly stimulate aquaporin-2 insertion by an ADH-independent mechanism; AQP2 trafficking to the luminal membrane is regulated by ADH-mediated cyclic AMP signaling, not by NCC blockade; this option describes a fictitious molecular pathway.

ANSWER: A

Rationale:

Diuretic-induced metabolic alkalosis develops through three mechanistically distinct but mutually reinforcing processes. First, volume contraction activates the renin-angiotensin system, and angiotensin II upregulates NHE3 on the luminal membrane of PCT cells, increasing proton secretion into the lumen and bicarbonate reabsorption into the blood — a process called contraction alkalosis. Second, diuretic-induced hypokalemia drives cellular potassium-hydrogen exchange: to maintain intracellular potassium, cells import potassium in exchange for exporting protons, raising extracellular bicarbonate further. Third, secondary aldosteronism resulting from volume depletion stimulates alpha-intercalated cells in the CD to secrete additional protons through H⁺-ATPase and H⁺-K⁺-ATPase pumps, generating new bicarbonate in the process. All three mechanisms operate simultaneously and each sustains the others, explaining why diuretic-induced metabolic alkalosis can be severe and persistent.

• Option B: Option B is incorrect: loop and thiazide diuretics do not directly inhibit carbonic anhydrase; carbonic anhydrase inhibition in the PCT is the mechanism of acetazolamide, which produces metabolic acidosis (not alkalosis) by reducing bicarbonate reabsorption — the opposite of what is described.
• Option C: Option C is incorrect: diuretics produce volume contraction (depletion), not volume expansion; contraction alkalosis is a real phenomenon but it reflects the concentration of bicarbonate when extracellular fluid volume is lost — not a dilutional effect; option C inverts the physiology.
• Option D: Option D is incorrect: while chloride depletion does contribute to maintaining metabolic alkalosis by reducing the availability of the anion that can be reabsorbed in exchange for bicarbonate, attributing the entire mechanism to chloride loss and excluding aldosterone, potassium, and NHE3 provides an incomplete and mechanistically incorrect account.
• Option E: Option E is incorrect: ROMK channels in the TAL transport potassium, not protons; proton secretion in the TAL is not a significant contributor to systemic acid-base balance, and no ROMK-mediated proton secretion pathway that is upregulated by NKCC2 blockade has been established.

ANSWER: C

Rationale:

Diuretic-induced hyperuricemia arises through two convergent mechanisms, both operating in the proximal convoluted tubule (PCT). First, both loop diuretics and thiazides are organic anions that are actively secreted into the tubular lumen via organic anion transporters (OAT1 and OAT3) on the basolateral membrane of the PCT. Urate is also secreted into the tubular lumen through OAT-dependent pathways. When loop diuretics or thiazides are present in high concentrations competing for OAT binding, they reduce urate secretion into the lumen, increasing the fraction of filtered urate that is retained. Second, volume contraction caused by sustained diuresis activates upregulation of URAT1 (SLC22A12), the proximal tubular urate-anion exchanger on the luminal membrane that mediates proximal urate reabsorption. Increased URAT1 activity retrieves more urate from the tubular lumen back into the blood, further raising serum uric acid. Together, reduced secretion and increased reabsorption both shift the net tubular handling of urate in the direction of retention.

• Option A: Option A is incorrect: loop and thiazide diuretics do not inhibit xanthine oxidase; xanthine oxidase inhibition is the mechanism of allopurinol and febuxostat, agents used to treat gout and hyperuricemia; diuretic-induced hyperuricemia is purely a tubular transport phenomenon.
• Option B: Option B is incorrect: diuretics cause volume contraction (not expansion), and passive urate reabsorption in the collecting duct is not the established mechanism; the primary sites of urate handling are in the PCT, not the CD.
• Option D: Option D is incorrect: hyperaldosteronism does not drive hyperuricemia through a urate-sodium cotransporter; the hyperuricemic effect of diuretics is mediated by OAT competition and URAT1 upregulation in the PCT, not by aldosterone-dependent collecting duct transport.
• Option E: Option E is incorrect: diuretics do not activate purine synthesis enzymes or inhibit uricase; humans lack functional uricase entirely (a historical evolutionary loss); the hyperuricemia mechanism is transport-based, not enzymatic.

ANSWER: E

Rationale:

Pancreatic beta-cell insulin secretion is initiated by a membrane potential-dependent sequence: glucose enters the beta-cell via GLUT2, is metabolized to increase the ATP/ADP ratio, and the rising ATP closes ATP-sensitive potassium (K_ATP) channels. K_ATP channel closure reduces the outward potassium current that maintains the resting membrane potential, causing membrane depolarization. Depolarization opens voltage-gated calcium channels, and the resulting calcium influx triggers insulin granule exocytosis. This entire sequence depends critically on the transmembrane potassium gradient. When extracellular potassium is reduced by thiazide-induced hypokalemia, the electrochemical gradient driving potassium out of the cell is diminished, and the resting membrane potential becomes more negative (hyperpolarized). A hyperpolarized beta-cell requires a greater ATP-driven depolarizing stimulus to reach the threshold for calcium channel opening, impairing glucose-stimulated insulin secretion. Clinically, this mechanism has been confirmed in pooled quantitative analyses linking the degree of thiazide-induced hypokalemia to the severity of glucose intolerance.

• Option A: Option A is incorrect: the primary glucose intolerance mechanism of thiazide-induced hypokalemia is beta-cell hyperpolarization and impaired insulin secretion, not hepatic K_ATP channel activation; hepatic K_ATP channels are not the established target of this mechanism.
• Option B: Option B is incorrect: while GLUT4 expression and skeletal muscle glucose disposal are relevant to overall glucose homeostasis, there is no established direct mechanism by which thiazide-induced hypokalemia transcriptionally reduces GLUT4 expression in skeletal muscle; the beta-cell mechanism is the pharmacologically established pathway.
• Option C: Option C is incorrect: GSK-3 inhibition would actually increase glycogen synthesis (not breakdown), and thiazide-induced hypokalemia does not directly inhibit GSK-3; this option describes a fictitious enzymatic mechanism.
• Option D: Option D is incorrect: thiazide-induced hypokalemia does not reduce muscarinic acetylcholine receptor signaling in pancreatic islets; while parasympathetic input does contribute to insulin secretion, this is not the established mechanism linking potassium depletion to beta-cell dysfunction.

ANSWER: B

Rationale:

The DOSE (Diuretic Optimization Strategies Evaluation) trial was a randomized, double-blind trial that addressed two simultaneous questions in ADHF management: high-dose versus low-dose diuresis, and continuous infusion versus intermittent bolus administration. For the dose comparison, patients in the high-dose arm received IV furosemide at 2.5 times their total oral daily dose. The trial found that high-dose IV furosemide was not inferior to low-dose in worsening renal function (the primary safety concern that previously restrained diuretic dosing in ADHF) and produced significantly greater net fluid loss and more rapid symptom relief, directly challenging the historically conservative approach to diuretic dosing in acute heart failure. These findings support dose escalation as the appropriate initial strategy in ADHF rather than conservative dosing that may leave patients undertreated.

• Option A: Option A is incorrect: the DOSE trial compared high-dose versus low-dose and bolus versus continuous infusion; neither continuous infusion nor low-dose was established as superior — the high-dose bolus arm performed as well as or better than the low-dose arm in outcomes that mattered to patients.
• Option C: Option C is incorrect: furosemide bioavailability is notoriously unreliable in ADHF because bowel wall edema impairs intestinal absorption; the DOSE trial examined IV administration strategies, not oral versus IV equivalence; oral furosemide is not reliably equivalent to IV in the hospitalized ADHF setting.
• Option D: Option D is incorrect: the DOSE trial compared dosing strategies for furosemide; it did not include torsemide as a study arm — the TRANSFORM-HF trial was the relevant furosemide-versus-torsemide comparison.
• Option E: Option E is incorrect: the DOSE trial found no significant difference between continuous infusion and bolus dosing in primary endpoints; it did not generate a recommendation against continuous infusion based on electrolyte abnormalities.

ANSWER: D

Rationale:

For first-line hypertension, chlorthalidone is the evidence-supported thiazide-class agent based on the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), which demonstrated that chlorthalidone-based therapy outperformed lisinopril-based therapy in reducing stroke and outperformed amlodipine-based therapy in reducing heart failure hospitalization in high-risk hypertensive patients. For resistant hypertension — defined as blood pressure uncontrolled on three optimally dosed agents including a diuretic — the PATHWAY-2 (Prevention and Treatment of Hypertension With Algorithm-Based Therapy 2) trial randomized patients to spironolactone, bisoprolol, doxazosin, or placebo as a fourth agent. Spironolactone produced the greatest home systolic blood pressure reduction, outperforming both bisoprolol and doxazosin, establishing mineralocorticoid receptor antagonism as the preferred fourth-line strategy and supporting the hypothesis that aldosterone excess is the dominant mechanism in true resistant hypertension.

• Option A: Option A is incorrect: furosemide is not the guideline-preferred first-line antihypertensive diuretic; its short duration of action and lack of outcome data comparable to ALLHAT make it unsuitable for routine hypertension management; chlorthalidone, not furosemide, is ALLHAT-supported.
• Option B: Option B is incorrect: ALLHAT compared chlorthalidone (not HCTZ) with amlodipine and lisinopril; PATHWAY-2 tested spironolactone as the most effective fourth agent, not amiloride; amiloride was not the comparator of interest in PATHWAY-2.
• Option C: Option C is incorrect: while chlorthalidone is correctly identified as first-line, furosemide is not the preferred fourth agent in resistant hypertension; PATHWAY-2 established spironolactone as superior to both beta-blockers and alpha-blockers as the fourth agent, and aldosterone antagonism — not loop diuresis — is the recommended strategy.
• Option E: Option E is incorrect: indapamide is a reasonable thiazide-like agent, and the ADVANCE trial supports its use in diabetes in combination with perindopril, but chlorthalidone backed by ALLHAT has broader outcome evidence for hypertension; PATHWAY-2 tested spironolactone (not eplerenone) as the fourth agent in resistant hypertension.

ANSWER: A

Rationale:

The cornerstone of acute hypercalcemia management is aggressive IV normal saline, which serves two purposes: it restores intravascular volume (hypercalcemia causes nephrogenic diabetes insipidus and volume depletion through polyuria) and promotes calciuresis by increasing GFR and tubular fluid flow. Once volume is adequately repleted, loop diuretics such as furosemide may be added to sustain urinary calcium excretion by abolishing the TAL lumen-positive potential that drives paracellular calcium reabsorption. Thiazide diuretics are absolutely contraindicated in hypercalcemia: their mechanism of action — reducing intracellular sodium in DCT cells, enhancing NCX1, and increasing TRPV5-mediated apical calcium entry — reduces urinary calcium excretion and would directly worsen the hypercalcemic state. This is a firm pharmacological contraindication, not merely a relative caution.

• Option B: Option B is incorrect: thiazides are absolutely contraindicated in hypercalcemia; their calcium-sparing effect does not redirect calcium to bone — it reduces renal calcium excretion by enhancing tubular reabsorption, which worsens hypercalcemia rather than correcting it.
• Option C: Option C is incorrect: loop diuretics are not contraindicated in hypercalcemia; their calciuretic effect is therapeutically useful; the risk of precipitating hypocalcemia by using loop diuretics in the setting of hypercalcemia is not a recognized clinical contraindication, and bisphosphonate timing is a separate management consideration.
• Option D: Option D is incorrect: loop diuretics are not contraindicated in hypercalcemia; IV saline plus loop diuretics is the standard acute pharmacological approach; IV zoledronic acid is used for sustained calcium lowering (particularly in malignancy-associated hypercalcemia) but is not the sole initial intervention.
• Option E: Option E is incorrect: furosemide should not be administered before IV saline; giving loop diuretics in a volume-depleted hypercalcemic patient would cause further volume contraction and reduce GFR, impairing the very calciuresis it is intended to promote; volume repletion must precede or accompany loop diuretic use.

ANSWER: C

Rationale:

Renal prostaglandins — principally PGE2 and prostacyclin (PGI2) — are produced locally in the kidney in response to physiological stressors including volume depletion, reduced cardiac output, and elevated angiotensin II. These prostaglandins serve two natriuretic functions: they directly inhibit tubular sodium reabsorption at multiple nephron segments, and they dilate the afferent arteriole to maintain GFR in states of reduced renal perfusion pressure. In patients with HFrEF or CKD, renal prostaglandin synthesis is already maximally stimulated to compensate for reduced cardiac output or nephron mass — making the kidney critically dependent on this prostaglandin-maintained vasodilation to preserve GFR. When NSAIDs inhibit COX-1 and COX-2, this prostaglandin production is eliminated. The resulting afferent arteriolar constriction reduces GFR, decreasing the tubular flow and sodium delivery that the loop diuretic needs to produce natriuresis, while simultaneously restoring tubular sodium reabsorption that prostaglandins were suppressing. In HFrEF and CKD, the hemodynamic consequences can be severe enough to precipitate AKI, and the diuretic response is markedly impaired. This interaction is frequently overlooked in patients who self-medicate with over-the-counter NSAIDs.

• Option A: Option A is incorrect: while NSAIDs are organic acids and could theoretically compete with loop diuretics at OAT sites, this is not the primary or clinically established mechanism of the interaction; the GFR-reducing effect through prostaglandin inhibition is the dominant mechanism.
• Option B: Option B is incorrect: NSAIDs do not block ENaC activity through adenylate cyclase signaling in the CD; PGE2 has complex, receptor subtype-dependent effects in the CD, but NSAID-induced ENaC blockade is not the established mechanism of diuretic resistance in this setting.
• Option D: Option D is incorrect: NSAIDs can reduce potassium excretion (hyperkalemia is a known adverse effect in susceptible patients), but the mechanism is reduced aldosterone synthesis from reduced angiotensin II, not direct ENaC blockade; this option does not correctly describe the diuretic resistance mechanism.
• Option E: Option E is incorrect: NSAIDs do not upregulate NKCC2 transcription through a COX-2-mediated pathway; no such prostaglandin-independent NKCC2 transcriptional upregulation has been established as the mechanism of NSAID-loop diuretic interaction.

ANSWER: E

Rationale:

Lithium is handled by the kidney similarly to sodium: it is freely filtered at the glomerulus and reabsorbed in the proximal convoluted tubule (PCT) via NHE3 and other sodium-permeable transporters. When loop or thiazide diuretics reduce plasma sodium through natriuresis, the kidney responds to the fall in sodium by activating compensatory mechanisms, including upregulation of NHE3-mediated sodium reabsorption in the PCT. Because lithium uses the same proximal transporters as sodium, this compensatory upregulation also increases lithium reabsorption. Thiazides are particularly dangerous in this context: the volume contraction they produce triggers renin-angiotensin-aldosterone activation and compensatory PCT sodium avidity that can double or triple plasma lithium concentration within days of diuretic initiation, converting a therapeutic lithium level to a toxic one. Loop diuretics also elevate lithium levels but to a lesser degree because the acute natriuresis from loop diuretics tends to be more rapid and self-limited. When a diuretic is genuinely required in a lithium-treated patient, amiloride is the preferred agent: it acts in the collecting duct on ENaC, it does not produce the PCT sodium avidity that drives proximal lithium reabsorption, and it does not significantly alter lithium clearance.

• Option A: Option A is incorrect: furosemide does not compete with lithium at the Na/K-ATPase; the mechanism of lithium toxicity is proximal tubular reabsorption driven by sodium depletion, not intracellular lithium accumulation via Na/K-ATPase competition; and thiazides are not safe — they are among the most dangerous diuretics in lithium-treated patients.
• Option B: Option B is incorrect: diuretic-induced lithium toxicity is not mediated by hyperkalemia or potassium-lithium neuronal exchange; it is mediated by reduced plasma sodium driving compensatory proximal lithium reabsorption and rising plasma lithium concentration.
• Option C: Option C is incorrect: thiazides are not preferred in lithium-treated patients and do not upregulate OCT-mediated lithium secretion; they are among the highest-risk agents for lithium toxicity.
• Option D: Option D is incorrect: loop and thiazide diuretics do meaningfully interact with lithium; lithium is not protein-bound — it is freely filtered and handled by the proximal tubule in a sodium-coupled fashion that is highly sensitive to volume status.

ANSWER: B

Rationale:

Digoxin inhibits the alpha-subunit of the myocardial Na/K-ATPase, reducing sodium extrusion and indirectly increasing intracellular calcium through the Na-Ca exchanger — the basis of its positive inotropic effect. At the Na/K-ATPase binding site, both potassium and magnesium are physiological competitors of digoxin: extracellular potassium in particular binds to the enzyme's extracellular face in a manner that partially displaces or antagonizes digoxin binding. When diuretics deplete both potassium and magnesium, this competitive antagonism is reduced, and digoxin binds the Na/K-ATPase more avidly and occupies a greater fraction of pump molecules at the same plasma drug concentration. The therapeutic-to-toxic ratio narrows dramatically — a digoxin dose that was well-tolerated at normal electrolyte levels becomes acutely toxic when potassium falls to 3.0 mEq/L or magnesium to 1.5 mg/dL. This interaction mandates routine potassium and magnesium monitoring in all patients receiving both digoxin and a diuretic.

• Option A: Option A is incorrect: while volume contraction can modestly reduce GFR and impair digoxin clearance, the primary and clinically dominant mechanism of diuretic-augmented digoxin toxicity is pharmacodynamic — increased Na/K-ATPase binding affinity from electrolyte depletion — not pharmacokinetic reduction in renal drug clearance.
• Option C: Option C is incorrect: furosemide is not a CYP3A4 or P-glycoprotein inducer; it does not lower plasma digoxin levels through metabolic induction; and NKCC2 is not expressed in the sinoatrial node.
• Option D: Option D is incorrect: diuretic-induced hyponatremia is not the mechanism of digoxin toxicity; the sodium gradient across the cardiomyocyte membrane is maintained by Na/K-ATPase activity, and the digoxin toxicity mechanism is hypokalemia/hypomagnesemia-driven displacement from the Na/K-ATPase, not a sodium gradient collapse.
• Option E: Option E is incorrect: diuretics do not significantly redistribute digoxin from plasma into skeletal muscle; the volume of distribution of digoxin is large and tissue-binding-dependent for reasons unrelated to diuretic use; plasma monitoring remains the standard approach to digoxin level assessment.

ANSWER: D

Rationale:

Diuretic resistance in the setting of CKD and volume overload is a common clinical problem with a rational stepwise approach. The first maneuver is to switch from oral to IV furosemide, addressing bowel wall edema-related absorption impairment and more reliably achieving adequate luminal drug concentrations. Dose escalation is next — OAT competition from uremic anions requires higher systemic doses to saturate the competition and restore luminal concentrations above the NKCC2 threshold. If dose escalation alone is inadequate, increasing the dosing frequency addresses post-diuretic sodium avidity: as each diuretic dose wanes, the nephron activates compensatory sodium reabsorption in the DCT and CD during the pharmacodynamic "dead zone" between doses; more frequent dosing reduces this avidity window. Concurrent nephrotoxin exposure — NSAIDs, aminoglycosides, contrast agents — should be identified and eliminated, as each reduces GFR and blunts the natriuretic response. If these measures are insufficient, adding metolazone (or another thiazide-like agent) creates sequential nephron blockade, preventing DCT compensatory sodium reabsorption that attenuates loop diuretic efficacy. This combination can produce dramatic natriuresis and requires electrolyte and renal function surveillance within 24–48 hours.

• Option A: Option A is incorrect: spironolactone is not first-line therapy for loop diuretic resistance; the initial steps are IV conversion, dose escalation, and frequency adjustment; mineralocorticoid receptor antagonism plays a role in specific contexts (resistant hypertension, HFrEF neurohormonal blockade) but not as the initial step in acute loop diuretic resistance.
• Option B: Option B is incorrect: ultrafiltration is not the recommended first-line approach to loop diuretic resistance; pharmacological optimization must be exhausted before considering mechanical fluid removal; CARRESS-HF data suggest ultrafiltration is not superior to pharmacological therapy in most ADHF patients with CKD.
• Option C: Option C is incorrect: loop diuretics have a ceiling effect beyond which further dose escalation produces no additional natriuresis; exceeding the ceiling dose increases toxicity (ototoxicity, electrolyte depletion) without additional benefit; the ceiling is a fundamental pharmacodynamic property, not an absence of one.
• Option E: Option E is incorrect: switching to torsemide and halving the dose does not resolve loop diuretic resistance; while torsemide's hepatic metabolism reduces OAT-dependent pharmacokinetic variability, it does not eliminate OAT competition at the tubular level, and dose reduction would worsen, not improve, the natriuretic response in a threshold-limited situation.